Neurocentria, Inc. Email Format

Biotechnology ResearchCalifornia, United States2-10 Employees

Neurocentria, Inc. is a late-stage biotechnology company focused on discovering and developing treatments for neurodegenerative and neuropsychiatric disorders, including ADHD, depression, and Alzheimer’s disease. Its research aims to address underlying pathophysiology, with the goal of preventing progression or reversing disease trajectories, improving symptoms, and enhancing patients’ cognitive performance and quality of life. The company’s lead program, NRCT-101SR, represents a novel treatment approach targeting new molecular mechanisms, with preclinical data indicating improvements in synaptic density, plasticity, and cognitive and emotional regulation, as well as potential benefits in models of neuroinflammation. Early clinical results suggest potential for faster mood improvement and symptom relief with minimal adverse effects, and the program has progressed toward pivotal and phase IIb/III trials in ADHD, Alzheimer’s disease, and major depressive disorder. Neurocentria is based in Walnut Creek, California, and has a focus on developing brain health therapies that are intended to be safe and beneficial for patients and communities. The company has announced ongoing clinical development efforts and recent activity related to its therapeutic programs.

Sign up for free to view info

Company overview Employee directory